Compliance with secondary prevention of ischemic stroke - A prospective evaluation

被引:96
作者
Sappok, T [1 ]
Faulstich, A [1 ]
Stuckert, E [1 ]
Kruck, H [1 ]
Marx, P [1 ]
Koennecke, HC [1 ]
机构
[1] Free Univ Berlin, Klinikum Benjamin Franklin, Stroke Unit, Dept Neurol, D-12200 Berlin, Germany
关键词
antithrombotic therapy; medical management; prevention; stroke; ischemic;
D O I
10.1161/01.STR.32.8.1884
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose-Compliance with pharmacological therapy is essential for the efficiency of secondary prevention of ischemic stroke. Few data exist regarding patient compliance with antithrombotic and risk factor treatment outside of controlled clinical trials. The aim of the present study was to assess the rate of and predictors for compliance with secondary stroke prevention 1 year after cerebral ischemia and to identify reasons for noncompliance. Methods-Patients with a diagnosis of ischemic stroke or TIA and antithrombotic discharge medication were prospectively recruited. At I year, the proportion of patients compliant with antithrombotic treatment and with medication for risk factors (eg, hypertension, diabetes, hyperlipidemia) was evaluated through structured telephone interviews. In addition, the reasons for nontreatment with antithrombotic and risk factor medication were determined. Independent predictors for compliance were analyzed by logistic regression analyses. Results-Of 588 consecutive patients admitted to our stroke unit, 470 had a discharge diagnosis of cerebral ischemia (TIA 26.2%. cerebral infarct 73.8%) and recommendations for antithrombotic therapy. At I year, 63 patients (13.4%) had died and 21 (4.5%) were lost to follow-up, thus, 386 could finally be evaluated. Of the patients, 87.6% were still on antithrombotic medication, and 70.2% were treated with the same agent prescribed on discharge. Of the patients with hypertension, diabetes, and hyperlipidemia, 90.8%, 84.9%. and 70.2% were still treated for their respective risk factors. Logistic regression analyses revealed age (OR 1.03, 95% CI 1.00 to 1.06), stroke severity on admission (OR 1.09, 95% Cl 1.00 to 1.20), and cardioembolic cause (OR 4.13. 95% Cl 1.23 to 13.83) as independent predictors of compliance. Conclusions-Compliance with secondary prevention in patients with ischemic stroke is rather good in the setting of our study. Higher age, a more severe neurological deficit on admission, and cardioembolic stroke cause are associated with better long-term compliance. Knowledge of these determinants may help to further improve the quality of stroke prevention.
引用
收藏
页码:1884 / 1889
页数:6
相关论文
共 31 条
[11]   Case-control study of stroke and the quality of hypertension control in north west England [J].
Du, XL ;
Cruickshank, K ;
McNamee, R ;
Saraee, M ;
Sourbutts, J ;
Summers, A ;
Roberts, N ;
Walton, E ;
Holmes, S .
BMJ-BRITISH MEDICAL JOURNAL, 1997, 314 (7076) :272-276
[12]  
Easton JD, 1999, NEUROLOGY, V53, pS32
[13]   Effect of antihypertensive treatment in patients having already suffered from stroke - Gathering the evidence [J].
Gueyffier, F ;
Boissel, JP ;
Boutitie, F ;
Pocock, S ;
Coope, J ;
Cutler, J ;
Ekbom, T ;
Fagard, R ;
Friedman, L ;
Kerlikowske, K ;
Perry, M ;
Prineas, R ;
Schron, E .
STROKE, 1997, 28 (12) :2557-2562
[14]   Health-related quality of life among long-term survivors of stroke - Results from the Auckland Stroke Study, 1991-1992 [J].
Hackett, ML ;
Duncan, JR ;
Anderson, CS ;
Broad, JB ;
Bonita, R .
STROKE, 2000, 31 (02) :440-447
[15]   Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis [J].
Hart, RG ;
Benavente, O ;
McBride, R ;
Pearce, LA .
ANNALS OF INTERNAL MEDICINE, 1999, 131 (07) :492-+
[16]   Antithrombotic and antihypertensive management 3 months after ischemic stroke - A prospective study in an inner city population [J].
Hillen, T ;
Dundas, R ;
Lawrence, E ;
Stewart, JA ;
Rudd, AG ;
Wolfe, CDA .
STROKE, 2000, 31 (02) :469-475
[17]   Risk factor modification,in stroke prevention - The experience of a stroke clinic [J].
Joseph, LN ;
Babikian, VL ;
Allen, NC ;
Winter, MR .
STROKE, 1999, 30 (01) :16-20
[18]   Stroke risk management - Changes in mainstream practice [J].
Kalra, L ;
Perez, I ;
Melbourn, A .
STROKE, 1998, 29 (01) :53-57
[19]  
LIU LS, 1995, CHINESE MED J-PEKING, V108, P710
[20]   Warfarin for atrial fibrillation - The patient's perspective [J].
ManSonHing, M ;
Laupacis, A ;
OConnor, A ;
Wells, G ;
Lemelin, J ;
Wood, W ;
Dermer, M .
ARCHIVES OF INTERNAL MEDICINE, 1996, 156 (16) :1841-1848